1-4 of 4
Marco Haselager
Close
Sort by
Journal Articles

Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax

Karoline Kielbassa, Marco Haselager, Danique Bax, Julie Dubois, Mark-David Levin, Peter E. Westerweel, Rebecka Svanberg, Carsten Utoft Niemann, Arnon P. Kater, Eric Eldering
Journal: Blood
Blood (2021) 138 (Supplement 1): 1545.
https://doi.org/10.1182/blood-2021-152222
Published: 2021
Journal Articles

Development of a Novel Lymph Node-Based 3D Culture System Promoting Chronic Lymphocytic Leukemia Proliferation and Survival

Marco Haselager, MSc, Eduard Perelaer, Arnon P. Kater, MDPhD, Eric Eldering, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-141962
Published: 2020
Journal Articles

Cross-Talk between Cytokine and NF-ĸb Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

Marco Haselager, MSc, Rachel Thijssen, Arnon P. Kater, Eric Eldering
Journal: Blood
Blood (2019) 134 (Supplement_1): 5449.
https://doi.org/10.1182/blood-2019-126788
Published: 2019
Journal Articles

Cross-Talk between Cytokine and NF-ĸB Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax

Rachel Thijssen, Marco Haselager, Elaine Willmore, Simon Mackay, Arnon P. Kater, MD, Eric Eldering
Journal: Blood
Blood (2017) 130 (Supplement 1): 4306.
https://doi.org/10.1182/blood.V130.Suppl_1.4306.4306
Published: 2017